Viewing Study NCT02575404

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:22 PM
Ignite Modification Date: 2026-03-10 @ 8:36 PM
Study NCT ID: NCT02575404
Status: COMPLETED
Last Update Posted: 2023-06-05
First Post: 2015-10-09
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
Sponsor: Providence Health & Services
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Melanoma View
None Non-Small Cell Lung Cancer View
None Squamous Cell Carcinoma of the Head and Neck View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic View
None Keytruda View
None pembrolizumab View
None GR-MD-02 View
None Galactoarabino-rhamnogalacturonate View
None Immunotherapy View